Pharma
BioResource-supported study finds ongoing brain injury caused by COVID-19 may not always be detected by routine tests
A new study published in Nature Communications details that markers of brain injury are present in the blood many months after COVID-19 infection, despite inflammation blood tests being normal. ...
NIHR BioResource Scientific Conference 2024
We are excited to announce the NIHR BioResource Scientific Conference will return later this year, hosted online on Wednesday 19 June 2024 from 9.30am to 12.30pm. ...
NIHR BioResource Scientific Conference to return in June 2024
NIHR BioResource are excited to announce the NIHR BioResource Scientific Conference will return later this year, hosted online on Wednesday 19 June 2024 from 9.30am to 12.30pm. Leading academics and industry researchers will present their recent work and the unique role of the NIHR BioR...
Cambourne Park Science & Technology Campus unveils new identity and welcomes first letting under new ownership
Rakon: Leading global precision timing designer and manufacturer chooses Cambourne Park Science & Technology Campus as location of choice for UK design hub. - Rakon secures 4,877 sq ft in Building 2020 with a ten year lease term. - New owner, Life Science REIT unveils new Campus ...
IT'S ALL ABOUT ME: Tangible leadership in 2024
Don't just lead, lead with impact!
Guardtech pledge to support NHS aseptic pharmacy units in 2024 after spike in enquiries
The Haverhill cleanroom construction experts have been inundated with enquiries from the nation’s healthcare heroes in recent months ...
CONEXEN - Informal Networking in Cambridge - 28 Feb 2024
CONEXEN is a networking group for professionals working in the life sciences, biopharma, medical devices and health tech industries. Join us on February 28th Pre-registration is still open. ...
Supporting a Phase III R&D strategy within the anti-infective space
Client Issue An emerging pharmaceutical company sought to evaluate Phase III development strategies for an anti-infective drug with potential to treat a range of patient populations. ...
Establishing real-world testing and treatment patterns for EGFR NSCLC patients
Client issue Oncology-focused biotech was looking to establish real-world testing and treatment patterns among EGFR NSCLC patients in US, EU, Japan, and Greater China (mainland, HK, and Taiwan). ...
Rare Disease: 2023 in Review
As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings. In the last five years, our consultants have undertaken over 700 client projects in rare diseases, constituting over 20% of our...